Despite an increase in prescription rates of mineralocorticoid receptor antagonists (MRAs) for patients with heart failure with reduced ejection fraction (HFrEF) in the United Kingdom from 2014 to ...

When corticosteroids are used for these purposes, the systemic agents with the least mineralocorticoid activity (sodium and water retention) should be used. Table 2 provides the anti-inflammatory ...

What you need to know Adrenal insufficiency is the inadequate production of the hormone cortisol from the adrenal glands. Global prevalence ranges from 0.4/100 000 (South Korea) to 15-22/100 000 ...

As Healio previously reported, in the main results of FINE-HEART, a pooled analysis of the FINEARTS-HF, FIDELIO-DKD and FIGARO-DKD trials of the nonsteroidal, selective mineralocorticoid receptor ...

"Current therapeutic approaches targeting aldosterone, such as mineralocorticoid receptor antagonists, have limitations -- among them, compensatory increases in serum aldosterone levels ...

At the time the licensing agreement was signed in October 2023, ocedurenone – an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA) – was being tested in a phase 3 trial in ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Primary cilia are cell signalling and ...

2 University College London Hospitals NHS Foundation Trust, London, UK Background and aims Mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalisation in heart failure with ...